A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors

Molecular Cancer Therapeutics

Volumn 4, Issue 6, 2005, Pages 948-955

  Weng, David E ^a   Masci, Paul A ^a   Radka, Susan F ^b   Jackson, T Elise ^b   Weiss, Patricia A ^a   Ganapathi, Ram ^a   Elson, Paul J ^a   Capra, William B ^c   Parker, Vann P ^b   Lockridge, Jennifer A ^b   Cowens, J Wayne ^b   Usman, Nassim ^b   Borden, Ernest C ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b Sirna Therapeutics Inc   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOZYME; ANTIBODY; RIBOZYME; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ADULT; AGED; ANTIBODY PRODUCTION; ARTICLE; BACKACHE; BRONCHOSPASM; BURNING SENSATION; CANCER GROWTH; CANCER RESISTANCE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TARGETING; DYSPNEA; EDEMA; ERYTHEMA; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEART ATRIUM FIBRILLATION; HUMAN; HYPOTENSION; INJECTION SITE REACTION; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; NASOPHARYNX CARCINOMA; NAUSEA; PAIN; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PRURITUS; SOLID TUMOR; TUMOR BIOPSY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASMS; RNA, CATALYTIC; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VON WILLEBRAND FACTOR;

EID: 21344433919     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-04-0210     Document Type: Article

References (20)

1. Usman N, Beigelman L, McSwiggen JA. Hammerhead ribozyme engineering. Curr Opin Struct Biol 1996 Aug;6:527-33.
2. Usman N, Blatt LM. Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics. J Clin Invest 2000 Nov; 106:1197-202.
3. Pavco PA, Bouhana KS, Gallegos AM, et al. Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clin Cancer Res 2000 May; 6:2094-103.
4. Parry TJ, Cushman C, Gallegos AM, et al. Bioactivity of anti-angiogenic ribozymes targeting flt-1 and KDR mRNA. Nucleic Acids Res 1999 Jul 1; 27:2569-77.
5. Silverman D, Berstrom R, Rothchild K, Chambers K, Weng DE, Kim J. Reduction in spontaneous metastases from 4T1 murine carcinoma using a ribozyme which targets flt-1 (VEGF receptor subtype 1) mRNA. 12th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy; 2001.
6. Sandberg JA, Bouhana KS, Gallegos AM, et al. Pharmacokinetics of an antiangiogenic ribozyme (Angiozyme) in the mouse. Antisense Nucleic Acid Drug Dev 1999 Jun;9:271-7.
7. Sandberg JA, Parker VP, Blanchard KS, et al. Pharmacokinetics and tolerability of an antiangiogenic ribozyme (Angiozyme) in healthy volunteers. J Clin Pharmacol 2000 Dec;40:1462-9.
8. Sandberg JA, Sproul CD, Blanchard KS, et al. Acute toxicology and pharmacokinetic assessment of a ribozyme (Angiozyme) targeting vascular endothelial growth factor receptor mRNA in the cynomolgus monkey. Antisense Nucleic Acid Drug Dev 2000 Jun;10:153-62.
9. Radka SF, Pasko C, Haeberli P, Beigelman L. The development of a monoclonal antibody specific for a 2(′)-C-allyl modification of uridine, and its use in the localization of ribozymes in vivo. Anal Biochem 2002 Aug 1; 307:40-6.
10. Padhani AR, Husband JE. Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies. Clin Radiol 2001 Aug;56:607-20.
11. Radka SF, Pasko C, Moyer CF, et al. Biomarker assessment of patient samples from a phase I/II study of Angiozyme in metastatic cancer patients. Third International Symposium on Anti-Angiogenic Agents; 2001.
12. Mannucci PM. Von Willebrand factor: a marker of endothelial damage? Arterioscler Thromb Vasc Biol 1998 Sep;18:1359-62.
13. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001 Feb 1; 19:843-50.
14. Margolin K, Gordon MS, Holmgren E, et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 2001 Feb 1;19:851-6.
15. Stopeck A, Sheldon M, Vahedian M, Cropp G, Gosalia R, Hannah A. Results of a phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. Clin Cancer Res 2002 Sep;8:2798-805.
16. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003 Jan 1;21:60-5.
17. Herbst RS, Mullani NA, Davis DW, et al. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol 2002 Sep 15;20: 3804-14.
18. Greenberg CS, Orthner CL. Procoagulant cofactor proteins. In: Lee GR, Foerster J, editors. Wintrobe's clinical hematology. 10th ed. Philadelphia: Lippincott; 1999. p. 702-9.
19. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003 Jun;9:669-76.
20. Kuenen BC, Levi M, Meijers JC, et al. Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. Arterioscler Thromb Vasc Biol 2002 Sep 1; 22:1500-5.